IL-17, IL-23 Therapies Lead Psoriasis Care
Overview
Biologic therapies, particularly IL-17 and IL-23 inhibitors, are associated with the highest likelihood of achieving near-complete skin clearance in patients with moderate to severe plaque psoriasis. Serious adverse events were similar across treatments, including placebo, indicating a favorable safety profile.
Background
Psoriasis is a chronic inflammatory skin condition that significantly impacts patients' quality of life. The emergence of biologic therapies targeting specific interleukins has transformed the management of moderate to severe plaque psoriasis. Understanding the efficacy and safety of these treatments is crucial for optimizing patient outcomes.
Data Highlights
| Therapy | PASI 90 Response | Serious Adverse Events |
|---|---|---|
| IL-17 Inhibitors | Specific PASI 90 response rate needed | Similar to placebo |
| IL-23 Inhibitors | Specific PASI 90 response rate needed | Similar to placebo |
| TNF Inhibitors | Lower efficacy | Similar to placebo |
Key Findings
- IL-17 inhibitors ranked highest for efficacy in achieving PASI 90, with specific rates needed.
- Serious adverse events were uncommon and similar across all systemic treatments.
- Infliximab, bimekizumab, ixekizumab, and risankizumab showed the highest PASI 90 response rates, with specific rates needed.
- Differences in onset of action were noted, with IL-17 inhibitors showing more rapid responses.
- Oral systemic therapies demonstrated lower PASI 90 response rates compared to biologics.
Clinical Implications
Clinicians should consider IL-17 and IL-23 inhibitors as first-line biologic options for patients with moderate to severe plaque psoriasis, particularly for those seeking rapid skin clearance. Ongoing assessment of long-term safety and efficacy is essential, as current data primarily reflect short-term outcomes and may not capture long-term effects.
Conclusion
The findings support the use of IL-17 and IL-23 inhibitors as effective treatments for achieving short-term skin clearance in psoriasis, reshaping expectations for disease management, but limitations regarding the short-term nature of the findings should be acknowledged.
References
- Armstrong AW, JAMA Network, 2023 -- IL-17, IL-23 Therapies Lead Psoriasis Care
- Journal of Crohn's and Colitis — Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?
- Journal of Gastroenterology — Emerging Therapeutic Strategies for Inflammatory Bowel Disorders
- Journal of Crohn's and Colitis — IL23R-Specific CAR Tregs for the Treatment of Crohn’s Disease
- Clinical Rheumatology — Assessment of the effectiveness and safety of interleukin-17A inhibitors for treating ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials
- Cochrane Evidence on Psoriasis Treatments
- https://www.guidelines.edf.one/uploads/attachments/clv20jpg13acsxcjrux8329gn-0-euroguiderm-pso-gl-mar-2024.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
